

Date: 03rd July, 2026

To,
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051.
Stock Code: VAISHALI

Sub: Allotment of 45,37,865 equity shares at an issue price of Rs. 20 per share on a Preferential Basis.

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and further to the outcome of the Board Meeting held on 13th February, 2026 and the approval of the shareholders by way of Special Resolution passed through Postal Ballot on 15th March, 2026 for issuance of equity shares on a preferential basis for consideration other than cash, we wish to inform you that the Board of Directors of the Company, by way of resolution passed through circulation today, i.e., 03rd July, 2026, has approved the allotment of 45,37,865 (Forty-Five Lakh Thirty-Seven Thousand Eight Hundred Sixty-Five) fully paid-up equity shares of face value of Rs. 2/- each at an issue price of Rs. 20/- per equity share (including a premium of Rs. 18/- per equity share), aggregating to Rs. 9,07,57,300/-, to Kesar Pharma Limited ("KPL") on a preferential basis for consideration other than cash, by way of swap of equity shares pursuant to the acquisition of 26.95% shareholding in KPL.

Consequent to the aforesaid allotment, the paid-up equity share capital of the Company has increased from Rs. 26,09,24,260/- comprising 13,04,62,130 equity shares of Rs. 2/- each to Rs. 26,99,99,990/- comprising 13,49,99,995 equity shares of Rs. 2/- each.

The aforesaid allotment has been made pursuant to the shareholders' approval and the In-Principle Approval received from the National Stock Exchange of India Limited vide Letter No. NSE/LIST/53490 dated 24th June, 2026.

The Company shall file an application to the stock exchanges for listing and trading approval for the newly allotted shares in due course.

The details required pursuant to Regulation 30 of the Listing Regulations read with Clause A(2)(2.1) of Annexure 18 of SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 ("Disclosure Circular"), are enclosed hereto as **Annexure - A**.

Kindly take the above on record.

Thanking You,
Yours Faithfully,

For Vaishali Pharma Limited

Vishwa Mekhia
Company Secretary Cum Compliance Officer

Annexure - A

The details as required under Regulation 30 of the Listing Regulations read with Clause A(2)(2.1) of Annexure 18 of the Disclosure Circular

Sr. No.	Particulars	Details								
1.	Type of securities proposed to be issued (viz. equity shares, convertibles etc.)	Equity shares of face value Rs. 2 (Rupee Two) each.								
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Preferential issue of equity shares in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“ ICDR Regulations ”), read with the Companies Act, 2013 and rules made thereunder.								
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Allotment of 45,37,865 (Forty-Five Lakh Thirty-Seven Thousand Eight Hundred Sixty Five Only) equity shares of the Company having face value of Rs. 2 (Rupee Two) each, which is not less than the price determined in accordance with Chapter V of the ICDR Regulations, for consideration other than cash, as discharge of the non-cash consideration for the subscription of 26.95% of the proposed total issued, subscribed and paid-up equity share capital of Kesar Pharma Limited (“ KPL ”)								
4.	Additional details:									
(a)	Name of the investor	<p>Kesar Pharma Limited</p> <table border="1"> <thead> <tr> <th>Sr. No.</th> <th>Name of the Allottee</th> <th>Category (Promoter/ Non-Promoter)</th> <th>No. of Equity Shares allotted</th> </tr> </thead> <tbody> <tr> <td>1.</td> <td>Kesar Pharma Limited</td> <td>Non-Promoter</td> <td>45,37,865</td> </tr> </tbody> </table>	Sr. No.	Name of the Allottee	Category (Promoter/ Non-Promoter)	No. of Equity Shares allotted	1.	Kesar Pharma Limited	Non-Promoter	45,37,865
Sr. No.	Name of the Allottee	Category (Promoter/ Non-Promoter)	No. of Equity Shares allotted							
1.	Kesar Pharma Limited	Non-Promoter	45,37,865							
Sr. No.	Particulars	Details								
(b)	Post Allotment of Equity Shares									

(i)	Outcome of Subscription	Details of the Shareholding and voting rights of the allottees are as under:																
		<table border="1"> <thead> <tr> <th rowspan="2">Name of the Allottee</th> <th colspan="2">Pre Preferential Shareholding</th> <th rowspan="2">No. of Equity Shares allotted</th> <th colspan="2">Post Preferential Shareholding</th> </tr> <tr> <th>No. of Shares</th> <th>%</th> <th>No. of Shares</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>Kesar Pharma Limited</td> <td>Nil</td> <td>Nil</td> <td>45,37,865</td> <td>45,37,865</td> <td>3.36 %</td> </tr> </tbody> </table>	Name of the Allottee	Pre Preferential Shareholding		No. of Equity Shares allotted	Post Preferential Shareholding		No. of Shares	%	No. of Shares	%	Kesar Pharma Limited	Nil	Nil	45,37,865	45,37,865	3.36 %
Name of the Allottee	Pre Preferential Shareholding			No. of Equity Shares allotted	Post Preferential Shareholding													
	No. of Shares	%	No. of Shares		%													
Kesar Pharma Limited	Nil	Nil	45,37,865	45,37,865	3.36 %													
(ii)	Issue Price/ Allotted Price	Issue price of Rs. 20/- each (Face Value Rs.2/- each + Premium Rs. 18/- each).																
(iii)	Number of Investors	1 (One)																
(c)	In case of convertibles - Intimation on conversion of securities or on lapse of the tenure of the instrument	Not applicable																
5.	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not applicable																
